
The a16z Show The Science and Supply of GLP-1s
58 snips
Jun 19, 2024 Brooke Boyarsky-Pratt, the CEO of KnownWell, revolutionizes the obesity medicine landscape with her personal journey battling obesity. She discusses the critical role of obesity-specific practitioners and patient-centric medical homes in fostering trust. The conversation delves into the science and impact of GLP-1 medications, highlighting their tailored applications in treatment. The challenges of cost and supply in the obesity sector are addressed, alongside a vision for a more empathetic, comprehensive approach to obesity care.
AI Snips
Chapters
Transcript
Episode notes
GLP-1s Explained
- GLP-1s mimic naturally occurring hormones, affecting insulin regulation, digestion, and fullness.
- These therapies have been around since 2005, though recently gaining more public attention.
Early GLP-1 Awareness
- Brooke first learned about GLP-1s in 2018 from an obesity medicine physician.
- Dr. Fitch predicted the significant impact of GLP-1s in the future.
Managing GLP-1 Expectations
- GLP-1s are effective but not a miracle cure, with varying weight loss results.
- Manage expectations and address potential side effects like nausea with proactive measures.

